Abstract
Although accumulation of amyloid β (Aβ) plaque is a major hallmark of Alzheimer's disease (AD), various pathologies have been suggested therapeutic targets. Therefore, therapies-targeting multiple pathologies would be required for effective managements of AD. Accordingly, natural products, which has multiple active ingredients, have been receiving a lot of attention. In this study, we tested whether standardized ethanol extract of leaves of Perilla frutescens var. acuta (L.) Britt. (Lamiaceae) (ELPF) could modulate various pathologies in AD using 5XFAD mice. ELPF blocked Aβ aggregation and disassembled pre-formed Aβ aggregates. ELPF blocked Aβ aggregates-induced LTP impairment and ELPF-disassembled Aβ aggregates failed to impair hippocampal LTP. Systemic administration of ELPF blocked Aβ aggregates-induced memory impairment in a passive avoidance test. ELPF-disassembled Aβ aggregates failed to impair passive avoidance memory. Prolonged administration of ELPF ameliorated memory impairments in 5XFAD mice. In the hippocampus of 5XFAD mice, ELPF administration significantly reduced Aβ deposits and neuroinflammation. These results demonstrate that ELPF could be a promising therapeutic candidate for AD.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.